Entropy Neurodynamics (ASX: ENP) is an Australian-listed company in the Healthcare sector with a market capitalisation of $49.0M and the 1028th-largest security on the ASX by market capitalisation. The ENP share price is $0.03, down 6.25% today. Shares have traded between $0.025 and $0.046 over the past 52 weeks. In its most recent reported period (ending 30 June 2025), Entropy Neurodynamics reported revenue of $0 and a net loss of $5.3M.
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
